Investigating Drug Treatment Costs and Patient Characteristics of Female Breast, Cervical, Colorectal, and Prostate Cancers in Antigua and Barbuda: A Retrospective Data Study (2017-2021).

Estrogen receptor-positive status (mean cost USD 6548.34, 95% CI 2094.05–11,002.63 compared to estrogen receptor-negative status) showed marginal significance, p -value < 0.1.

also in 2,005 other papers

Cancer-specific variables that showed statistically significant mean drug treatment costs ( p ≤ 0.05) were marginally significant but clinically relevant or were found to be clinically relevant based on the literature.

also in 8,505 other papers

Characteristics observed to be marginally statistically significant in the multivariable linear model were age at presentation with an increase in mean costs to USD 1709.00 (95% CI 21.34–7621.29) for every one-year increase in age at presentation; late-stage disease with a reduction in mean costs to USD 1817.32 (95% CI 4.45–7631.77) when compared to early-stage disease; PSA level ≤ 20 ng/mL with reduced mean costs to USD 1619.26 (95% CI 6.50–6892.32) when compared to PSA level not stated ( Table 4 ).

also in 373 other papers